FDA advised to license three anti-HIV agents.
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors; D006801:Humans; D007546:Isoquinolines; D019259:Lamivudine; D011804:Quinolines; D019258:Saquinavir; D018119:Stavudine; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000031:analogs & derivatives
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D019259:Lamivudine; D016047:Zalcitabine; D018119:Stavudine; D019258:Saquinavir